Okur-Chung neurodevelopmental syndrome (OCNDS) is an ultra-rare autosomal dominant neurodevelopmental disorder caused by heterozygous pathogenic variants in CSNK2A1, which encodes the catalytic CK2alpha subunit of protein kinase CK2. Core manifestations include global developmental delay, intellectual disability, severe speech and language impairment, hypotonia, dysmorphic features, microcephaly in a substantial subset, dysphagia and other gastrointestinal problems, seizures in a minority, and occasional congenital heart abnormalities. Current mechanistic evidence does not support a single uniform gain-of-function model; instead, pathogenic variants can reduce CK2alpha kinase activity, alter subcellular localization, or rewire substrate specificity, converging on abnormal phosphoregulation and synaptic dysfunction in the developing nervous system.
Ask a research question about Okur-Chung Neurodevelopmental Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Okur-Chung Neurodevelopmental Syndrome
creation_date: "2026-04-09T17:17:18Z"
updated_date: "2026-05-10T14:45:31Z"
category: Mendelian
synonyms:
- OCNDS
- Okur-Chung syndrome
- CSNK2A1-related neurodevelopmental disorder
parents:
- Neurodevelopmental disorder
- Intellectual disability syndrome
disease_term:
preferred_term: Okur-Chung neurodevelopmental syndrome
term:
id: MONDO:0014893
label: Okur-Chung neurodevelopmental syndrome
mappings:
mondo_mappings:
- term:
id: MONDO:0014893
label: Okur-Chung neurodevelopmental syndrome
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: Primary MONDO disease term for this entry.
notes: >-
Repo rare-disease cross-reference tables also list OMIM:617062 and
Orphanet:689422 for this disorder, but the current schema does not expose
dedicated OMIM/Orphanet mapping slots.
description: >-
Okur-Chung neurodevelopmental syndrome (OCNDS) is an ultra-rare autosomal
dominant neurodevelopmental disorder caused by heterozygous pathogenic
variants in CSNK2A1, which encodes the catalytic CK2alpha subunit of protein
kinase CK2. Core manifestations include global developmental delay,
intellectual disability, severe speech and language impairment, hypotonia,
dysmorphic features, microcephaly in a substantial subset, dysphagia and
other gastrointestinal problems, seizures in a minority, and occasional
congenital heart abnormalities. Current mechanistic evidence does not support
a single uniform gain-of-function model; instead, pathogenic variants can
reduce CK2alpha kinase activity, alter subcellular localization, or rewire
substrate specificity, converging on abnormal phosphoregulation and synaptic
dysfunction in the developing nervous system.
prevalence:
- population: Global reported literature
percentage: Ultra-rare
notes: >-
No population-based prevalence estimate was identified. Recent disease
overviews consistently describe OCNDS as an ultra-rare disorder.
evidence:
- reference: PMID:39070093
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Okur-Chung neurodevelopmental syndrome (OCNDS) is an ultra-rare disorder
caused by variants in the CSNK2A1 gene.
explanation: >-
Recent disease-roadmap literature explicitly classifies OCNDS as
ultra-rare, supporting rarity even though a formal population prevalence
estimate is not yet available.
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
OCNDS is inherited as an autosomal dominant disorder. Most reported cases
are de novo, but familial transmission with variable expressivity is now
established.
evidence:
- reference: PMID:27048600
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
we report five patients with a neurodevelopmental disorder associated
with developmental delay, intellectual disability, behavioral problems,
hypotonia, speech problems, microcephaly, pachygyria and dysmorphic
features in whom we have identified de novo missense and canonical splice
site mutations in CSNK2A1, the gene encoding CK2α, the catalytic subunit
of protein kinase CK2, a ubiquitous serine/threonine kinase composed of
two regulatory (β) and two catalytic (α and/or α') subunits.
explanation: >-
The original OCNDS report established recurrent de novo heterozygous
CSNK2A1 variants as the predominant inheritance pattern.
- reference: PMID:37491870
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pedigree showing the autosomal dominant inheritance pattern of CSNK21
variants in families presenting with OCNDS.
explanation: >-
Subsequent family reports demonstrate that inherited dominant CSNK2A1
disease also occurs, so OCNDS is not exclusively de novo.
pathophysiology:
- name: CSNK2A1-dependent CK2alpha kinase dysfunction
description: >-
OCNDS is initiated by pathogenic heterozygous variants in CSNK2A1, which
encodes CK2alpha, the catalytic subunit of the ubiquitous serine/threonine
kinase CK2. Across studied variants, the dominant biochemical consequence
is not uniform: many missense alleles reduce catalytic activity and alter
localization, whereas others preserve activity but shift substrate
specificity. The convergent result is dysregulated CK2-dependent
phosphorylation during neurodevelopment.
gene:
preferred_term: CSNK2A1
term:
id: hgnc:2457
label: CSNK2A1
molecular_functions:
- preferred_term: protein serine/threonine kinase activity
term:
id: GO:0004674
label: protein serine/threonine kinase activity
biological_processes:
- preferred_term: protein phosphorylation
term:
id: GO:0006468
label: protein phosphorylation
modifier: DYSREGULATED
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
downstream:
- target: Synaptic phosphoregulation defects
description: >-
Altered CK2alpha function perturbs phosphorylation of neuronal proteins,
predisposing to defective synaptic maturation and plasticity.
evidence:
- reference: PMID:33944995
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Here, we show that 15 different missense CK2α mutations lead to varying
degrees of loss of kinase activity as recombinant purified proteins and
when mutants are ectopically expressed in mammalian cells.
explanation: >-
Functional studies show that many OCNDS-linked missense variants reduce
CK2alpha catalytic activity.
- reference: PMID:33944995
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Our data argue that reduced kinase activity and abnormal localization of
CK2α may underlie the OCNDS phenotype.
explanation: >-
Patient-derived fibroblast and cell-expression data support abnormal
kinase activity and localization as pathogenic mechanisms.
- reference: PMID:35517865
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Contrary to prior speculation, the mutation does not result in a complete
loss of function, but rather shifts the substrate specificity of the
kinase.
explanation: >-
At least some recurrent OCNDS alleles act through altered substrate
recognition rather than simple catalytic loss, supporting mechanistic
heterogeneity.
- name: Synaptic phosphoregulation defects
description: >-
OCNDS-linked CK2alpha dysfunction alters phosphorylation of pre- and
postsynaptic proteins, impairs glutamatergic synapse maturation, and
disrupts synaptic plasticity in hippocampal circuits. These changes provide
a plausible mechanistic bridge from CSNK2A1 variant effects to cognitive,
language, behavioral, and seizure-related manifestations.
cell_types:
- preferred_term: glutamatergic neuron
term:
id: CL:0000679
label: glutamatergic neuron
biological_processes:
- preferred_term: synapse organization
term:
id: GO:0050808
label: synapse organization
modifier: DYSREGULATED
- preferred_term: regulation of synaptic plasticity
term:
id: GO:0048167
label: regulation of synaptic plasticity
modifier: DYSREGULATED
- preferred_term: synaptic transmission, glutamatergic
term:
id: GO:0035249
label: synaptic transmission, glutamatergic
modifier: DYSREGULATED
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
downstream:
- target: Global developmental delay
description: >-
Impaired synaptic maturation and plasticity likely contribute to the core
developmental and cognitive phenotype.
- target: Seizures
description: >-
Altered glutamatergic signaling and synaptic plasticity provide a
plausible substrate for epileptiform manifestations in a subset of
patients.
evidence:
- reference: PMID:39367055
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Phosphoproteome analysis from brain tissue revealed alterations in the
phosphorylation status of major pre- and postsynaptic proteins of
heterozygous knock-in mice.
explanation: >-
A knock-in mouse model of a recurrent OCNDS variant shows broad
phosphoregulation abnormalities affecting synaptic proteins.
- reference: PMID:39367055
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
In congruence, we detect reduced synaptic maturation in hippocampal
neurons and attenuated long-term potentiation in the hippocampus of
knock-in mice.
explanation: >-
The same model demonstrates impaired synaptic maturation and plasticity,
linking CK2alpha dysfunction to circuit-level abnormalities.
genetic:
- name: CSNK2A1
association: Causative
gene_term:
preferred_term: CSNK2A1
term:
id: hgnc:2457
label: CSNK2A1
notes: >-
Most reported OCNDS alleles are heterozygous missense variants in the
kinase domain, frequently clustering in functionally constrained regions
such as the activation segment, ATP/GTP-binding loop, and holoenzyme
binding pocket. Newer reports also show that inherited and null variants
can produce OCNDS, often with milder or atypical presentations, arguing
against a single missense-only disease model.
variants:
- name: Kinase-domain missense variants
description: >-
Predominant OCNDS variant class. Most disease-associated missense changes
lie within the protein kinase domain and many cluster near the CK2
holoenzyme binding pocket or in loop regions associated with greater
phenotypic burden.
clinical_significance: PATHOGENIC
evidence:
- reference: PMID:29240241
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All except 1 variant reported in this cohort are spatially located on
the binding pocket of the holoenzyme.
explanation: >-
Early case-series evidence shows strong clustering of OCNDS missense
variants in a functionally important CK2alpha surface.
- reference: PMID:40677894
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Mutations in the glycine-rich loop-known to bind both ATP and the
regulatory CK2β subunit-were linked to significantly higher symptom
burden and more non-seizure neurological symptoms.
explanation: >-
Natural-history data support clinically relevant genotype-phenotype
stratification within the missense-variant class.
- name: Null variants
description: >-
Frameshift and other predicted null variants expand the OCNDS allelic
spectrum and may act through haploinsufficiency, often with a milder
phenotype than classic missense disease.
clinical_significance: PATHOGENIC
evidence:
- reference: PMID:38444259
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Transcription analysis revealed this variant may lead to
nonsense-mediated mRNA decay, suggesting haploinsufficiency as a
potential disease mechanism.
explanation: >-
A familial frameshift case supports haploinsufficiency as one plausible
mechanism for non-missense OCNDS alleles.
- reference: PMID:38444259
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
individuals carrying CSNK2A1 null variants may exhibit a diminished
frequency of symptoms linked to language deficits, dysmorphic facial
features, or intellectual disability, consequently presenting an
overall milder phenotype when compared to those with missense variants.
explanation: >-
Review of reported cases suggests null alleles can present with a
comparatively attenuated phenotype.
phenotypes:
- category: Neurological
name: Global developmental delay
frequency: VERY_FREQUENT
description: >-
Global developmental delay is a core and nearly universal OCNDS feature,
often affecting both motor and cognitive milestones from infancy or early
childhood.
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
evidence:
- reference: PMID:29240241
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
frequently occurring clinical features including neurodevelopmental delay
(93%), gastrointestinal (57%), musculoskeletal (57%) and immunological
(43%) abnormalities.
explanation: >-
This multicenter case series quantifies neurodevelopmental delay in the
great majority of reported patients.
- reference: PMID:40677894
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All individuals reported speech/language delay, with additional common
features including global developmental delay, neurological symptoms, and
gastrointestinal issues.
explanation: >-
Recent natural-history data confirm that global developmental delay
remains a conserved core OCNDS feature across variant groups.
- category: Neurological
name: Intellectual disability
frequency: VERY_FREQUENT
description: >-
Intellectual disability is part of the core neurodevelopmental phenotype,
though severity varies and may be attenuated in some null-variant families.
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: PMID:29383814
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Consistent with previously reported patients, patients in this series had
apparent intellectual disability, swallowing difficulties, and hypotonia.
explanation: >-
Detailed phenotyping in an 11-patient series confirms intellectual
disability as a recurring, recognizable part of the syndrome.
- reference: PMID:38444259
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
individuals carrying CSNK2A1 null variants may exhibit a diminished
frequency of symptoms linked to language deficits, dysmorphic facial
features, or intellectual disability, consequently presenting an overall
milder phenotype when compared to those with missense variants.
explanation: >-
Newer genotype-phenotype work supports intellectual disability as a core
feature while also indicating variant-class-dependent variability.
- category: Neurological
name: Delayed speech and language development
frequency: VERY_FREQUENT
description: >-
Severe speech and language delay is one of the most consistent OCNDS
manifestations and often remains disproportionately prominent even among
patients with otherwise variable severity.
phenotype_term:
preferred_term: Delayed speech and language development
term:
id: HP:0000750
label: Delayed speech and language development
evidence:
- reference: PMID:40677894
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
All individuals reported speech/language delay, with additional common
features including global developmental delay, neurological symptoms, and
gastrointestinal issues.
explanation: >-
Natural-history data show speech and language delay in every surveyed
individual, supporting classification as a core hallmark.
- reference: PMID:27048600
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
we report five patients with a neurodevelopmental disorder associated
with developmental delay, intellectual disability, behavioral problems,
hypotonia, speech problems, microcephaly, pachygyria and dysmorphic
features in whom we have identified de novo missense and canonical splice
site mutations in CSNK2A1, the gene encoding CK2α, the catalytic subunit
of protein kinase CK2, a ubiquitous serine/threonine kinase composed of
two regulatory (β) and two catalytic (α and/or α') subunits.
explanation: >-
The original report already identified speech impairment as part of the
core syndrome.
- category: Behavioral
name: Behavioral abnormalities
description: >-
Behavioral manifestations are part of the OCNDS phenotype and include
hyperactivity, repetitive movements, social interaction deficits, and
autistic features across published cohorts and disease overviews.
phenotype_term:
preferred_term: Behavioral abnormality
term:
id: HP:0000708
label: Atypical behavior
evidence:
- reference: PMID:33944995
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
intellectual disability, behavioral problems (hyperactivity, repetitive
movements and social interaction deficits), hypotonia, epilepsy and
language/verbalization deficits.
explanation: >-
The OCNDS functional review explicitly includes behavioral problems with
hyperactivity, repetitive movements, and social interaction deficits in
the core syndrome description.
- reference: PMID:39070093
supports: SUPPORT
evidence_source: OTHER
snippet: >-
OCNDS presents with symptoms at varying severity, including developmental
delay/intellectual disabilities, autism, disrupted sleep, speech
delays/inability to speak, short stature, and, in ~25% of cases,
epilepsy.
explanation: >-
The patient-organization roadmap further supports autism as part of the
broader behavioral phenotype described in OCNDS.
- category: Neurological
name: Hypotonia
frequency: FREQUENT
description: >-
Generalized hypotonia is common early in life and contributes to delayed
gross motor development and feeding/swallowing difficulties.
phenotype_term:
preferred_term: Hypotonia
term:
id: HP:0001252
label: Hypotonia
evidence:
- reference: PMID:29383814
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Consistent with previously reported patients, patients in this series had
apparent intellectual disability, swallowing difficulties, and hypotonia.
explanation: >-
The largest early dedicated clinical series confirms hypotonia as a
recurring core manifestation.
- reference: PMID:40677894
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Variants in loop regions were associated with significantly younger age
at diagnosis and a higher frequency of hypotonia.
explanation: >-
Natural-history work confirms hypotonia remains common and may be more
prominent in specific variant groups.
- category: Neurological
name: Microcephaly
frequency: FREQUENT
description: >-
Reduced head circumference is a common but historically under-recognized
feature of OCNDS, particularly in specific variant locations.
phenotype_term:
preferred_term: Microcephaly
term:
id: HP:0000252
label: Microcephaly
evidence:
- reference: PMID:39497417
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
our cohort together with those individuals reported in the literature
revealed that OCNDS individuals, on average, have a smaller head
circumference with one-third presenting with microcephaly.
explanation: >-
This recent cohort-level reanalysis supports microcephaly as a common
syndrome feature rather than a rare outlier.
- category: Gastrointestinal
name: Dysphagia
frequency: FREQUENT
description: >-
Swallowing dysfunction is a recurring gastrointestinal manifestation and can
contribute to feeding problems in early childhood.
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
evidence:
- reference: PMID:29383814
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Consistent with previously reported patients, patients in this series had
apparent intellectual disability, swallowing difficulties, and hypotonia.
explanation: >-
The dedicated 11-patient clinical study directly supports dysphagia as a
recurrent clinical problem in OCNDS.
- category: Cardiac
name: Congenital heart defect
frequency: OCCASIONAL
description: >-
Congenital heart abnormalities occur in a minority of patients but are
clinically important enough to justify recognition during baseline
assessment.
phenotype_term:
preferred_term: Congenital heart defect
term:
id: HP:0001627
label: Abnormal heart morphology
evidence:
- reference: PMID:29383814
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Congenital heart abnormalities were identified in nearly 30% of the
patients, representing a newly recognized CSNK2A1 clinical association.
explanation: >-
This cohort established congenital heart disease as an important although
non-universal component of the OCNDS phenotype.
- category: Neurological
name: Seizures
frequency: OCCASIONAL
description: >-
Epileptic seizures occur in a minority of affected individuals and likely
arise from the broader network and synaptic dysfunction caused by CK2alpha
dysregulation.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:39070093
supports: SUPPORT
evidence_source: OTHER
snippet: >-
OCNDS presents with symptoms at varying severity, including developmental
delay/intellectual disabilities, autism, disrupted sleep, speech
delays/inability to speak, short stature, and, in ~25% of cases,
epilepsy.
explanation: >-
Recent disease-roadmap literature summarizes epilepsy as affecting about a
quarter of reported OCNDS cases.
notes: >-
Treatments were not curated as a dedicated section because current literature
supports symptom-based multidisciplinary management rather than any approved
disease-modifying therapy. Candidate biomarkers such as variant-location
stratification remain investigational and were therefore not promoted to a
biomarker section.
references:
- reference: PMID:27048600
title: "De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features."
findings: []
- reference: PMID:29383814
title: "Extending the phenotype associated with the CSNK2A1-related Okur-Chung syndrome-A clinical study of 11 individuals."
findings: []
- reference: PMID:29240241
title: "Okur-Chung neurodevelopmental syndrome: Eight additional cases with implications on phenotype and genotype expansion."
findings: []
- reference: PMID:33944995
title: "Okur-Chung neurodevelopmental syndrome-linked CK2α variants have reduced kinase activity."
findings: []
- reference: PMID:35517865
title: "The Okur-Chung Neurodevelopmental Syndrome Mutation CK2(K198R) Leads to a Rewiring of Kinase Specificity."
findings: []
- reference: PMID:39367055
title: "Missense mutation in the activation segment of the kinase CK2 models Okur-Chung neurodevelopmental disorder and alters the hippocampal glutamatergic synapse."
findings: []
- reference: PMID:39497417
title: "Expanding the phenotypic spectrum of CSNK2A1-associated Okur-Chung neurodevelopmental syndrome."
findings: []
- reference: PMID:40677894
title: "OCNDS core features are conserved across variants, with loop-region mutations driving greater symptom burden."
findings: []
- reference: DOI:10.1002/ajmg.a.63642
title: 'Patient with a heterozygous pathogenic variant in <scp><i>CSNK2A1</i></scp> gene: A new case to update the <scp>Okur–Chung</scp> neurodevelopmental syndrome'
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: 'The autosomal dominant Okur–Chung neurodevelopmental syndrome (OCNDS: OMIM #617062) is a rare neurodevelopmental disorder first described in 2016.'
supporting_text: 'The autosomal dominant Okur–Chung neurodevelopmental syndrome (OCNDS: OMIM #617062) is a rare neurodevelopmental disorder first described in 2016.'
evidence:
- reference: DOI:10.1002/ajmg.a.63642
reference_title: 'Patient with a heterozygous pathogenic variant in <scp><i>CSNK2A1</i></scp> gene: A new case to update the <scp>Okur–Chung</scp> neurodevelopmental syndrome'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: 'The autosomal dominant Okur–Chung neurodevelopmental syndrome (OCNDS: OMIM #617062) is a rare neurodevelopmental disorder first described in 2016.'
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1002/mgg3.2398
title: '<scp>Okur‐Chung</scp> neurodevelopmental syndrome: Implications for phenotype and genotype expansion'
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Okur‐Chung neurodevelopmental syndrome (OCNDS) is a rare autosomal dominant disorder caused by pathogenic variants in CSNK2A1.
supporting_text: Okur‐Chung neurodevelopmental syndrome (OCNDS) is a rare autosomal dominant disorder caused by pathogenic variants in CSNK2A1.
evidence:
- reference: DOI:10.1002/mgg3.2398
reference_title: '<scp>Okur‐Chung</scp> neurodevelopmental syndrome: Implications for phenotype and genotype expansion'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Okur‐Chung neurodevelopmental syndrome (OCNDS) is a rare autosomal dominant disorder caused by pathogenic variants in CSNK2A1.
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1002/mgg3.70166
title: A Case of <scp> <i>CSNK2A1</i> </scp> Gene Variant Causing Okur‐Chung Syndrome and Analysis of the Clinical Phenotypic Spectrum
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: To investigate the clinical features and genetic etiology of one child with Okur‐Chung neurodevelopmental syndrome (OCNDS).
supporting_text: To investigate the clinical features and genetic etiology of one child with Okur‐Chung neurodevelopmental syndrome (OCNDS).
evidence:
- reference: DOI:10.1002/mgg3.70166
reference_title: A Case of <scp> <i>CSNK2A1</i> </scp> Gene Variant Causing Okur‐Chung Syndrome and Analysis of the Clinical Phenotypic Spectrum
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: To investigate the clinical features and genetic etiology of one child with Okur‐Chung neurodevelopmental syndrome (OCNDS).
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1073/pnas.2018740118
title: A complex of distal appendage–associated kinases linked to human disease regulates ciliary trafficking and stability
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Significance Primary cilia (PC) are sensory organelles essential for the development and maintenance of adult tissues.
supporting_text: Significance Primary cilia (PC) are sensory organelles essential for the development and maintenance of adult tissues.
evidence:
- reference: DOI:10.1073/pnas.2018740118
reference_title: A complex of distal appendage–associated kinases linked to human disease regulates ciliary trafficking and stability
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Significance Primary cilia (PC) are sensory organelles essential for the development and maintenance of adult tissues.
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1101/2024.01.09.574075
title: 'Characterizing CSNK2A1 Mutant-Induced Morphological Phenotypes in Zebrafish (Danio rerio): Insights into Okur-Chung Neurodevelopmental Syndrome (OCNDS)'
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is a rare, autosomal dominant disorder caused by heterozygous pathogenic variants in the CSNK2A1 gene.
supporting_text: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is a rare, autosomal dominant disorder caused by heterozygous pathogenic variants in the CSNK2A1 gene.
evidence:
- reference: DOI:10.1101/2024.01.09.574075
reference_title: 'Characterizing CSNK2A1 Mutant-Induced Morphological Phenotypes in Zebrafish (Danio rerio): Insights into Okur-Chung Neurodevelopmental Syndrome (OCNDS)'
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is a rare, autosomal dominant disorder caused by heterozygous pathogenic variants in the CSNK2A1 gene.
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1111/cge.14408
title: Inherited <scp>CSNK2A1</scp> variants in families with <scp>Okur‐Chung</scp> neurodevelopmental syndrome
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Inherited <scp>CSNK2A1</scp> variants in families with <scp>Okur‐Chung</scp> neurodevelopmental syndrome
supporting_text: Inherited <scp>CSNK2A1</scp> variants in families with <scp>Okur‐Chung</scp> neurodevelopmental syndrome
- reference: DOI:10.1159/000522353
title: 'Clinical Features of Okur-Chung Neurodevelopmental Syndrome: Case Report and Literature Review'
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Autosomal dominant pathogenic variations in the CSNK2A1 gene cause Okur-Chung neurodevelopmental syndrome (OCNDS).
supporting_text: Autosomal dominant pathogenic variations in the CSNK2A1 gene cause Okur-Chung neurodevelopmental syndrome (OCNDS).
evidence:
- reference: DOI:10.1159/000522353
reference_title: 'Clinical Features of Okur-Chung Neurodevelopmental Syndrome: Case Report and Literature Review'
supports: SUPPORT
evidence_source: OTHER
snippet: Autosomal dominant pathogenic variations in the CSNK2A1 gene cause Okur-Chung neurodevelopmental syndrome (OCNDS).
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1159/000530585
title: A Case of Okur-Chung Neurodevelopmental Syndrome with a Novel, de novo Variant on the <i>CSNK2A1</i> Gene in a Turkish Patient
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: 'Okur-Chung neurodevelopmental syndrome (OCNDS; #617062) has been associated with heterozygous mutations in the CSNK2A1 gene (*115440) mapped on the chromosome’s 20p13 region.'
supporting_text: 'Okur-Chung neurodevelopmental syndrome (OCNDS; #617062) has been associated with heterozygous mutations in the CSNK2A1 gene (*115440) mapped on the chromosome’s 20p13 region.'
evidence:
- reference: DOI:10.1159/000530585
reference_title: A Case of Okur-Chung Neurodevelopmental Syndrome with a Novel, de novo Variant on the <i>CSNK2A1</i> Gene in a Turkish Patient
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: 'Okur-Chung neurodevelopmental syndrome (OCNDS; #617062) has been associated with heterozygous mutations in the CSNK2A1 gene (*115440) mapped on the chromosome’s 20p13 region.'
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.1177/26330040241249763
title: 'Patient organization perspective: a research roadmap for Okur-Chung Neurodevelopmental Syndrome'
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Okur-Chung neurodevelopmental syndrome (OCNDS) is an ultra-rare disorder caused by variants in the CSNK2A1 gene.
supporting_text: Okur-Chung neurodevelopmental syndrome (OCNDS) is an ultra-rare disorder caused by variants in the CSNK2A1 gene.
evidence:
- reference: DOI:10.1177/26330040241249763
reference_title: 'Patient organization perspective: a research roadmap for Okur-Chung Neurodevelopmental Syndrome'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Okur-Chung neurodevelopmental syndrome (OCNDS) is an ultra-rare disorder caused by variants in the CSNK2A1 gene.
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
- reference: DOI:10.3389/fmolb.2022.850661
title: The Okur-Chung Neurodevelopmental Syndrome Mutation CK2K198R Leads to a Rewiring of Kinase Specificity
found_in:
- Okur_Chung_neurodevelopmental_syndrome-deep-research-falcon.md
findings:
- statement: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is caused by heterozygous mutations to the CSNK2A1 gene, which encodes the alpha subunit of protein kinase CK2.
supporting_text: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is caused by heterozygous mutations to the CSNK2A1 gene, which encodes the alpha subunit of protein kinase CK2.
evidence:
- reference: DOI:10.3389/fmolb.2022.850661
reference_title: The Okur-Chung Neurodevelopmental Syndrome Mutation CK2K198R Leads to a Rewiring of Kinase Specificity
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: Okur-Chung Neurodevelopmental Syndrome (OCNDS) is caused by heterozygous mutations to the CSNK2A1 gene, which encodes the alpha subunit of protein kinase CK2.
explanation: Deep research cited this publication as relevant literature for Okur Chung neurodevelopmental syndrome.
OCNDS is a Mendelian neurodevelopmental syndrome caused by heterozygous pathogenic variants in CSNK2A1 (encoding the catalytic α subunit of protein kinase CK2). It is typically de novo but can be inherited in an autosomal dominant pattern. Clinical diagnosis is supported by characteristic neurodevelopmental features, but the definitive diagnosis requires molecular genetic testing demonstrating a heterozygous pathogenic/likely pathogenic CSNK2A1 variant. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, belnap2023inheritedcsnk2a1variants pages 1-2)
GeneReviews explicitly lists the synonym “CSNK2A1-Related Neurodevelopmental Syndrome.” (chung2022okurchungneurodevelopmentalsyndrome pages 1-3)
Most current clinical knowledge is derived from aggregated literature (GeneReviews synthesis of published cases) supplemented by individual case reports, family series, and patient-registry/family-survey data (CSNK2A1 Foundation, Simons Searchlight). (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, belnap2023inheritedcsnk2a1variants pages 1-2, rushing2024patientorganizationperspective pages 1-2)
Primary causal factor: Germline heterozygous pathogenic variants in CSNK2A1 (casein kinase 2 alpha 1), affecting CK2 function in neural development and other cellular processes. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, rushing2024patientorganizationperspective pages 1-2)
For OCNDS (a monogenic disorder), “risk factors” are primarily genetic: - De novo CSNK2A1 variants account for most probands. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, rushing2024patientorganizationperspective pages 2-4) - Familial (inherited) CSNK2A1 variants are now documented, shifting counseling from a purely de novo paradigm. (belnap2023inheritedcsnk2a1variants pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2)
No environmental or infectious risk factors were identified in the retrieved evidence.
No genetic protective alleles, protective environmental factors, or gene–environment interactions were identified in the retrieved evidence.
| Clinical feature / developmental metric | Frequency / statistic | Cohort / source note | Suggested HPO term(s) | Citation |
|---|---|---|---|---|
| Developmental delay / intellectual disability | 35/35 (100%) with developmental delay / ID; ID reported in about three quarters overall | GeneReviews Table 2 summarized from 36 clinically described individuals; language generally more affected than gross motor | HP:0001263 Developmental delay; HP:0001249 Intellectual disability | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6, chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Dysmorphic facial features | 29/36 (80.6%) | Often round face and short, broad nasal tip; nonspecific facial dysmorphism | HP:0001999 Facial dysmorphism; HP:0000311 Round face; HP:0012805 Broad nose | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Behavioral issues | 27/36 (75.0%) | Includes stereotypies, autism spectrum disorder, tantrums/aggression, ADHD | HP:0000729 Autistic behavior; HP:0000733 Stereotypy; HP:0007018 Attention deficit hyperactivity disorder | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Hypotonia | 22/36 (61.1%); described as about two thirds | Usually mild, beginning in infancy/childhood | HP:0001252 Muscular hypotonia | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Brain MRI abnormalities | 11/20 (55.0%) | Nonspecific; examples include delayed myelination, thin corpus callosum, small anterior pituitary | HP:0012444 Abnormal brain MRI; HP:0001273 Corpus callosum hypoplasia; HP:0012447 Delayed myelination | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Musculoskeletal findings | 15/36 (41.7%) | Kyphoscoliosis, loose joints, hernia | HP:0002650 Scoliosis; HP:0001382 Joint hypermobility; HP:0001537 Umbilical hernia | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Feeding difficulties | 14/36 (38.9%) | From infancy to childhood; can include poor suck / difficulty with solids | HP:0011968 Feeding difficulties; HP:0002033 Dysphagia | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Postnatal short stature | 14/36 (38.9%) | Generally 2–3 SD below mean | HP:0004322 Short stature | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Difficulty gaining weight / failure to thrive | 13/36 (36.1%) | Growth impairment common | HP:0001508 Failure to thrive; HP:0002028 Poor weight gain | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Sleep issues | 13/36 (36.1%) in GeneReviews cohort; 77% families reporting sleep-related disruptions in 2022 Simons Searchlight survey | Likely related to disrupted circadian rhythm; family-reported burden may exceed literature-derived frequency | HP:0002360 Sleep disturbance; HP:0002363 Circadian rhythm sleep disorder | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6, rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2) |
| Microcephaly / smaller head size | 12/36 (33.3%) | Usually postnatal or relative; congenital microcephaly uncommon | HP:0000252 Microcephaly | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Seizures / epilepsy | 11/36 (30.6%) in GeneReviews cohort; approximately 25% in 2024 overview | Seizure prevalence may be underreported; some events may occur during sleep | HP:0001250 Seizure; HP:0001251 Ataxia if associated neurologic issues present | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6, rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2) |
| Ataxia / gait difficulties / poor coordination | 9/36 (25.0%) | Variable motor coordination deficits | HP:0001251 Ataxia; HP:0001288 Gait disturbance; HP:0002370 Poor coordination | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Autism spectrum disorder | ~1/4 affected individuals | Subset of behavioral phenotype | HP:0000729 Autistic behavior | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Stereotypic movements | ~1/3 affected individuals | Common behavioral manifestation | HP:0000733 Stereotypy | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| ADHD | ~1/5 affected individuals | Attention and hyperactivity phenotype | HP:0007018 Attention deficit hyperactivity disorder | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Congenital heart abnormalities | About one-third in Blanc review; atrial septal defect reported in 3 unrelated individuals in GeneReviews | Cardiac involvement is variable and not universal | HP:0001627 Abnormality of the cardiovascular system; HP:0001631 Atrial septal defect | (blanc2024patientwitha pages 4-5, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Average age: sitting independently | 11 months | Early developmental milestone average | HP:0001270 Delayed ability to sit | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Average age: walking independently | 28.8 months | Gross motor milestone average | HP:0001270 Motor delay; HP:0001288 Gait disturbance | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Average age: first meaningful words | 38.3 months | Language milestone average; language more impaired than gross motor | HP:0000750 Delayed speech and language development | (chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
Table: This table summarizes the most consistently reported clinical features and developmental milestones for Okur-Chung neurodevelopmental syndrome, integrating GeneReviews 2022 frequency data with newer 2024 patient-organization survey statistics for sleep and seizure burden. It is useful for phenotype curation, HPO mapping, and quick comparison of literature-based versus family-reported symptom prevalence.
Direct standardized QoL instruments (e.g., EQ-5D, SF-36, PROMIS) were not reported in the retrieved texts. However, a 2022 Simons Searchlight family survey (summarized in 2024) ranked the top reported issues as: (1) intellectual disability/developmental delay, (2) language delay/inability to speak, and (3) sleep issues, with “77% of families reporting sleep-related disruptions.” (rushing2024patientorganizationperspective pages 2-4)
| Variant / class | Evidence type | Inheritance | Key phenotype / cohort note | Molecular / mechanistic interpretation | ACMG / classification note | Publication date | URL | Citation |
|---|---|---|---|---|---|---|---|---|
| p.Lys198Arg (K198R), recurrent missense | Familial clinical series; also noted as the most frequently reported de novo pathogenic variant | Both inherited and previously reported de novo | In 3 families with inherited OCNDS, common manifestations across 8 individuals included DD/ID (8/8), speech delay (7/8), behavioral problems (4/8), hypotonia (3/8), dysmorphic facial features (5/8); marked inter- and intra-familial variability | Not consistent with simple loss of function; K198R causes a “rewiring” of CK2 specificity with decreased +1 acidic preference, decreased threonine phosphorylation, increased tyrosine phosphorylation, and altered tyrosine motif preference | Not specified in retrieved familial/mechanistic excerpts | 2023-07; 2022-04 | https://doi.org/10.1111/cge.14408; https://doi.org/10.3389/fmolb.2022.850661 | (belnap2023inheritedcsnk2a1variants pages 1-2, belnap2023inheritedcsnk2a1variants pages 2-2, caefer2022theokurchungneurodevelopmental pages 1-2) |
| p.Glu27Lys, missense | Familial clinical series | Inherited (maternal transmission) | Reported in Family 3 with two affected sons; supports preserved fertility and autosomal dominant transmission in OCNDS | No variant-specific biochemical assay in retrieved evidence; supports variable expressivity rather than obligate severe de novo-only disease | Not specified in retrieved excerpt | 2023-07 | https://doi.org/10.1111/cge.14408 | (belnap2023inheritedcsnk2a1variants pages 1-2, belnap2023inheritedcsnk2a1variants pages 2-2) |
| p.Arg47Gln, missense | Case report with literature review | Heterozygous pathogenic variant; inheritance not specified in retrieved excerpt | Patient had DD, ID, generalized hypotonia, speech delay, short stature, microcephaly, dysmorphic features; lacked sleep disturbance, seizures, and gait difficulty | Falls in/near ATP/GTP-binding loop region implicated in broader phenotypic range; ATP/GTP-loop variants are reported to cause the widest range of phenotypes | Described as pathogenic in case report context; no ACMG criteria quoted in retrieved excerpt | 2024-05 | https://doi.org/10.1002/ajmg.a.63642 | (blanc2024patientwitha pages 1-2, blanc2024patientwitha pages 4-5, blanc2024patientwitha pages 4-4) |
| p.Met381GlyfsTer32, frameshift | Turkish case report | De novo | Hypotonia, developmental delay, dysmorphic features, abnormal MRI with mildly underdeveloped myelination and ventricular changes | First reported OCNDS-associated frameshift in retrieved evidence; predicted elongated C-terminal mutant protein may be nonfunctional and may disrupt CK2α interactions/depolymerization | Classified as likely pathogenic under ACMG-2015; PS2 and PM2 explicitly noted | 2024-05 (online first 2023-05-26) | https://doi.org/10.1159/000530585 | (zhuri2024acaseof pages 3-6, zhuri2024acaseof pages 1-3, zhuri2024acaseof pages 6-7) |
| p.Tyr323Leufs*16, truncating frameshift | Familial Chinese case report with RNA studies | Inherited (proband and mother) | Proband had recurrent generalized tonic-clonic seizures, language impairment, ID; mother had postnatal hernias, splenomegaly, infection predisposition, but no major DD/ID, illustrating variable expressivity | Transcript with frameshift variant was not detected and total CSNK2A1 product was reduced by ~50%, supporting nonsense-mediated decay and haploinsufficiency; authors suggest null variants may produce milder phenotypes than missense variants | No ACMG wording quoted in retrieved excerpt | 2024-03 | https://doi.org/10.1002/mgg3.2398 | (nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 2-5) |
| p.Arg191Ter (R191X), truncating/nonsense | Zebrafish functional model | Experimental model (not patient inheritance) | Produced among the most severe and consistent zebrafish phenotypes, including enlarged head, reduced body size, yolk sac defects, and spinal curvature | Co-injection of wild-type CSNK2A1 mRNA significantly rescued R191X-induced abnormalities; together with CK2 inhibitor phenocopy, this supports CK2 dysfunction and is compatible with dominant-negative effects for some mutants | Not applicable | 2024-01-11 | https://doi.org/10.1101/2024.01.09.574075 | (hassett2024characterizingcsnk2a1mutantinduced pages 7-9, hassett2024characterizingcsnk2a1mutantinduced pages 1-4, hassett2024characterizingcsnk2a1mutantinduced pages 4-7) |
| p.Tyr50Cys (Y50C), missense | Human case report/review and zebrafish model | De novo in reported human case | Human OCNDS with DD/short stature/ID; in zebrafish, Y50C caused severe morphological abnormalities | Located in ATP/GTP-binding loop; structural analyses suggest impaired protein activation and destabilization of CK2 heterotetramer; wild-type co-injection attenuated zebrafish phenotype, again suggesting mutant interference with CK2 function in at least some contexts | Human case classified pathogenic by ACMG in 2025 review excerpt (PS2 + PS4_Moderate + PM2_Supporting + PP2 + PP3), but not from 2023-2024 sources | 2024-01-11; 2025-12 | https://doi.org/10.1101/2024.01.09.574075; https://doi.org/10.1002/mgg3.70166 | (hassett2024characterizingcsnk2a1mutantinduced pages 7-9, hassett2024characterizingcsnk2a1mutantinduced pages 4-7, li2025acaseof pages 1-2, li2025acaseof pages 3-4) |
| OCNDS-associated missense variants overall | Review / mechanistic synthesis | Mostly de novo, but inherited cases now established | Most OCNDS variants are missense and cluster in functional regions of the kinase domain; registry data reported 82 distinct variants and 22 deletions | Mechanisms are heterogeneous and likely variant-dependent: reduced activity for many variants, altered substrate specificity for K198R, haploinsufficiency/NMD for truncating alleles, and possible dominant-negative effects suggested by zebrafish rescue experiments and variant-specific localization differences | Variant-specific ACMG status varies; no single classification applies | 2024-01; 2022-04; 2024-03 | https://doi.org/10.1177/26330040241249763; https://doi.org/10.3389/fmolb.2022.850661; https://doi.org/10.1002/mgg3.2398 | (rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2, caefer2022theokurchungneurodevelopmental pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2) |
Table: This table summarizes representative CSNK2A1 variants reported in Okur-Chung neurodevelopmental syndrome, their inheritance patterns, associated phenotypes, and currently supported molecular mechanisms. It is useful for linking specific variant classes to pathogenic models such as altered substrate specificity, haploinsufficiency, or possible dominant-negative effects.
Key 2023–2024 updates: - Inherited OCNDS: Belnap et al. (Clinical Genetics; accepted 2023-07-16; https://doi.org/10.1111/cge.14408) report three families with inherited CSNK2A1 variants, supporting preserved fertility and variable expressivity. (belnap2023inheritedcsnk2a1variants pages 1-2) - Frameshift/truncating alleles: Nan et al. (Mol Genet Genomic Med; accepted 2024-01-31; https://doi.org/10.1002/mgg3.2398) present a familial frameshift with RNA evidence consistent with nonsense-mediated decay (NMD) and haploinsufficiency (∼50% decreased CSNK2A1 product). (nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 2-5) - Frameshift case report: Zhuri et al. (Molecular Syndromology; 2024-05; https://doi.org/10.1159/000530585) report a novel, de novo CSNK2A1 frameshift classified as likely pathogenic per ACMG criteria. (zhuri2024acaseof pages 1-3, zhuri2024acaseof pages 3-6)
No validated modifier genes or disease-specific epigenetic signatures were identified in the retrieved evidence.
However, registry data indicate that deletions (structural variants) are present among individuals with OCNDS (recorded as “22 distinct deletions” in the CSNK2A1 Foundation registry). (rushing2024patientorganizationperspective pages 2-4)
No specific environmental, lifestyle, or infectious contributors were reported for OCNDS in the retrieved evidence; OCNDS is best characterized as a Mendelian CSNK2A1-associated condition. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, rushing2024patientorganizationperspective pages 1-2)
OCNDS pathophysiology is variant-dependent, with evidence supporting multiple (not mutually exclusive) molecular mechanisms: - Altered kinase substrate specificity (neomorphic/rewiring): For the common K198R variant, Caefer et al. report: “Contrary to prior speculation, the mutation does not result in a loss of function, but rather shifts the substrate specificity of the kinase,” including increased tyrosine phosphorylation preference and motif changes. (Frontiers in Molecular Biosciences; 2022-04; https://doi.org/10.3389/fmolb.2022.850661) (caefer2022theokurchungneurodevelopmental pages 1-2) - Loss-of-function / haploinsufficiency for truncating alleles: Nan et al. report that in a familial frameshift, “the transcript with the frameshift variant was not detected” and there was “A ∼50% decrease in the CSNK2A1 product,” supporting NMD and haploinsufficiency. (Mol Genet Genomic Med; 2024-03; https://doi.org/10.1002/mgg3.2398) (nan2024okur‐chungneurodevelopmentalsyndrome pages 2-5, nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2) - Dominant-negative or interference effects for some mutants: Zebrafish mutant-expression phenotypes can be rescued by co-injection of wild-type CSNK2A1 mRNA; the authors interpret this as consistent with mutant interference with CK2 function. (bioRxiv; posted 2024-01-11; https://doi.org/10.1101/2024.01.09.574075) (hassett2024characterizingcsnk2a1mutantinduced pages 7-9, hassett2024characterizingcsnk2a1mutantinduced pages 4-7)
Loukil et al. provide cell-biological evidence connecting CSNK2A1 to ciliogenesis and showing that OCNDS-linked variants can cause ciliary defects: - CSNK2A1 identified “as an important modulator of TTBK2 function in cilia trafficking.” (PNAS; 2021-04; https://doi.org/10.1073/pnas.2018740118) (loukil2021acomplexof pages 1-2) - “CSNK2A1 is a centrosomal protein concentrated at the mother centriole and associated with the distal appendages.” (loukil2021acomplexof pages 1-2) - “Overexpression of Csnk2a1 variants associated with OCNDS causes ciliary structural abnormalities.” (loukil2021acomplexof pages 1-2)
Sleep disturbance is common clinically and is often framed as circadian disruption. The 2024 roadmap/perspective connects CK2 to circadian regulation, noting CK2 modulates PER2 and that a Drosophila dominant-negative CK2 mutant induced marked circadian period lengthening (~33 h). (rushing2024patientorganizationperspective pages 2-4)
The dominant affected system is the nervous system (neurodevelopmental delay/ID, seizures, hypotonia, behavior). Secondary involvement can include growth/endocrine issues (short stature; occasional partial growth hormone deficiency), gastrointestinal/nutrition (feeding difficulties), musculoskeletal (scoliosis/kyphosis, hypermobility, hernias), and occasionally cardiovascular congenital defects. (chung2022okurchungneurodevelopmentalsyndrome pages 3-6, chung2022okurchungneurodevelopmentalsyndrome pages 1-3, blanc2024patientwitha pages 4-5)
Experimental and review evidence highlights CK2α abundance in brain and CSNK2A1 localization to centrosomal/distal appendage regions relevant to cilia. (rushing2024patientorganizationperspective pages 2-4, loukil2021acomplexof pages 1-2)
UBERON suggestions (non-exhaustive): brain (UBERON:0000955); cerebral cortex (UBERON:0000956); hippocampus (UBERON:0001954); heart (UBERON:0000948).
Typically manifests in infancy/early childhood with hypotonia, feeding issues, speech and motor delay, and developmental delay. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6)
GeneReviews provides milestone averages (sitting ~11 months; walking ~28.8 months; first meaningful words ~38.3 months). (chung2022okurchungneurodevelopmentalsyndrome pages 3-6)
Atypical later diagnosis/milder phenotypes exist; a 2024 report includes an affected 31-year-old proband with relatively mild early history and later functional outcomes (graduated technical secondary school, worked as cashier), illustrating variable expressivity. (nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2)
Robust staging frameworks and long-term survival statistics were not available in the retrieved evidence.
Autosomal dominant; most cases are de novo, but inherited familial cases are established, and low-level parental mosaicism is recognized. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, belnap2023inheritedcsnk2a1variants pages 1-2)
A 2022 literature review notes that early female predominance was not sustained as more cases were reported, with an approximate male:female ratio ~1:1. (khamirani2022clinicalfeaturesof pages 5-6)
No population prevalence or incidence estimates were present in the retrieved evidence.
No OCNDS-specific laboratory biomarkers are established; brain MRI abnormalities are nonspecific and present in ~55% (11/20) of those imaged in the GeneReviews-derived cohort. (chung2022okurchungneurodevelopmentalsyndrome pages 3-6)
| Domain | Recommendation / finding | Details / implementation notes | Suggested MAXO term(s) | Citation |
|---|---|---|---|---|
| Diagnostic framework | No formal consensus clinical diagnostic criteria published | Diagnosis is established in a proband with suggestive findings plus a heterozygous pathogenic/likely pathogenic CSNK2A1 variant | MAXO:0000000 Not applicable | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Suggestive clinical findings | Core phenotype prompting evaluation | Mild-to-moderate developmental delay or intellectual disability, generalized hypotonia in infancy/childhood, speech delay, plus infant feeding difficulties, seizures, behavioral findings, slow growth/failure to thrive, or nonspecific dysmorphic features | MAXO:0000000 Not applicable | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| First-line genetic workup | Chromosomal microarray (CMA) may be an initial test in DD/ID evaluation | GeneReviews notes molecular testing in a child with DD or older person with ID may begin with CMA; useful before or alongside broader sequencing workflows | MAXO:0000127 Genetic testing | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Targeted sequencing strategy | Intellectual disability / neurodevelopmental multigene panel including CSNK2A1 | Useful after nondiagnostic CMA; panel composition varies by lab and some ID panels may omit CSNK2A1 because OCNDS is rare | MAXO:0000127 Genetic testing | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Preferred broad sequencing | Exome sequencing (ES/WES) is most commonly used | GeneReviews states ES is most commonly used; 2024 and 2023 reports repeatedly used WES/trio-WES in real-world diagnosis of simplex and familial cases | MAXO:0000127 Genetic testing | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, belnap2023inheritedcsnk2a1variants pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, blanc2024patientwitha pages 1-2, zhuri2024acaseof pages 3-6) |
| Genome sequencing | Genome sequencing (GS/WGS) is also possible and increasingly important | Blanc et al. note diagnoses are likely to rise with growing use of exome and genome sequencing | MAXO:0000127 Genetic testing | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, blanc2024patientwitha pages 1-2) |
| Single-gene testing | Usually not recommended as routine first choice | GeneReviews: single-gene CSNK2A1 testing is rarely useful and typically not recommended for undifferentiated DD/ID | MAXO:0000127 Genetic testing | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Segregation testing | Confirm inheritance status with parental studies | Recent reports used Sanger/co-segregation to show de novo or inherited variants, informing counseling and recurrence risk | MAXO:0000127 Genetic testing | (nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, belnap2023inheritedcsnk2a1variants pages 1-2, zhuri2024acaseof pages 3-6) |
| RNA studies for truncating variants | Consider transcript analysis when variant mechanism is uncertain | In a 2024 familial truncating case, RT-PCR/qRT-PCR showed absent mutant transcript and ~50% reduction in CSNK2A1 product, supporting NMD/haploinsufficiency | MAXO:0000127 Genetic testing | (nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 2-5) |
| Feeding management | Feeding therapy | Recommended for persistent feeding issues and difficulty transitioning feeds | MAXO:0001327 Feeding therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Nutritional support | Consider gastrostomy tube placement | For persistent feeding/swallowing problems or poor growth | MAXO:0001108 Gastrostomy tube placement | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Short stature management | Consider growth hormone therapy when endocrinology evaluation supports partial GH deficiency | GeneReviews specifies use when indicated by an endocrinologist; partial GH deficiency has been reported in OCNDS | MAXO:0000122 Hormone replacement therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Seizure management | Standard anti-seizure medication under neurology care | Used for epilepsy/seizures ranging from single events to intractable epilepsy | MAXO:0000058 Anticonvulsant therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Immunologic management | Consider intravenous immune globulin (IVIG) for demonstrated hypogammaglobulinemia | GeneReviews recommends immunologist-directed IVIG where IgG deficiency is documented | MAXO:0000079 Immunoglobulin therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Motor rehabilitation | Physical therapy / rehabilitation medicine | For hypotonia, motor coordination problems, and gait issues | MAXO:0000011 Physical therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Functional rehabilitation | Occupational therapy | Standard supportive developmental therapy for function and daily living skills | MAXO:0000012 Occupational therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Communication therapy | Speech/language therapy | Important because language is often more impaired than gross motor development | MAXO:0000013 Speech therapy | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Sleep management | Monitor and treat sleep disturbance symptomatically | Sleep issues are common, often related to circadian rhythm disturbance; 77% of families in a 2022 survey reported sleep-related disruptions | MAXO:0000184 Sleep management | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6, rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2) |
| Cardiac/other organ management | Standard care for associated comorbidities | Includes scoliosis, constipation, congenital heart defects, renal anomalies/pelviectasis, and sleep disorders | MAXO:0000000 Supportive care | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Surveillance at each visit | Growth, nutrition, feeding safety, constipation, neurologic review, development/behavior, infections, sleep | GeneReviews recommends repeated assessment of growth parameters, feeding/oral safety, seizures/tone/movement disorders/coordination, developmental progress, behavior, unusual infections, and sleep disturbance | MAXO:0000400 Clinical monitoring | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) |
| Periodic surveillance | Ophthalmology evaluation every 1-3 years | Because ophthalmologic findings can occur, though usually nonspecific/infrequent | MAXO:0000400 Clinical monitoring | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, chung2022okurchungneurodevelopmentalsyndrome pages 3-6) |
| Genetic counseling | Counsel as autosomal dominant, usually de novo but occasionally inherited or due to parental mosaicism | Once a familial pathogenic variant is known, prenatal testing and preimplantation genetic testing are possible | MAXO:0000154 Genetic counseling | (chung2022okurchungneurodevelopmentalsyndrome pages 1-3, belnap2023inheritedcsnk2a1variants pages 1-2) |
| Real-world implementation update | Molecular testing remains the only diagnostic method currently available | 2024 roadmap article states there are no approved disease-specific treatments and diagnosis currently relies on molecular genetic testing; registry and research infrastructure are being expanded | MAXO:0000127 Genetic testing; MAXO:0000000 Supportive care | (rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2) |
Table: This table summarizes practical diagnostic and management recommendations for Okur-Chung neurodevelopmental syndrome, combining the GeneReviews 2022 care framework with key 2023-2024 updates on real-world genomic diagnosis and symptom burden. It is useful for rapid clinical curation and for mapping interventions to suggested MAXO terms.
Key implementation data points: - GeneReviews: “Exome sequencing is most commonly used,” and single-gene testing is “typically NOT recommended” for undifferentiated DD/ID. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3) - Case series/case reports (2023–2024) show routine WES/trio-WES plus Sanger segregation for inherited vs de novo determination, and RNA studies to support NMD for truncating variants. (belnap2023inheritedcsnk2a1variants pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, zhuri2024acaseof pages 3-6)
A structured differential diagnosis list was not included in the retrieved excerpts. GeneReviews notes that CSNK2A1 can be part of broader ID multigene panels and that panels may include other genes of interest (implying a broad neurodevelopmental differential). (chung2022okurchungneurodevelopmentalsyndrome pages 1-3)
Quantitative survival, mortality, and life expectancy data were not identified in the retrieved corpus. Available evidence supports substantial phenotypic heterogeneity including mild adult presentations (familial null variant case), and variable seizure burden with possible underrecognition. (nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, rushing2024patientorganizationperspective pages 2-4)
There are no approved disease-modifying treatments; management is supportive and targeted to manifestations. (rushing2024patientorganizationperspective pages 1-2, chung2022okurchungneurodevelopmentalsyndrome pages 1-3)
Key interventions and MAXO mappings are summarized in Artifact-03 (feeding therapy, gastrostomy, GH therapy when indicated, antiseizure medications, IVIG for hypogammaglobulinemia, PT/OT/speech, sleep management, and surveillance). (chung2022okurchungneurodevelopmentalsyndrome pages 1-3)
No interventional OCNDS-specific trials were identified in the retrieved clinical-trials search, but there is major observational natural history infrastructure (Simons Searchlight) that includes CSNK2A1. (NCT01238250 chunk 1)
Primary prevention of de novo cases is not currently feasible. Prevention is primarily via genetic counseling and reproductive options: - GeneReviews states that once a familial CSNK2A1 pathogenic variant is identified, prenatal testing and preimplantation genetic testing are possible. (chung2022okurchungneurodevelopmentalsyndrome pages 1-3)
No naturally occurring veterinary disease analogs were identified in the retrieved evidence.
| Resource / model | Type | Key design / scope | Main findings / utility | Publication / status date | URL | Citation |
|---|---|---|---|---|---|---|
| Zebrafish CSNK2A1 overexpression model | In vivo model organism | Human wild-type or mutant CSNK2A1 mRNAs injected at the single-cell stage in zebrafish; variants tested included D156E, K198R, R47G/R47Q, Y50C, R191X | Mutant overexpression caused variant-specific developmental defects including aberrant yolk sac, enlarged head, reduced body size, and curved spine; wild-type overexpression alone did not cause phenotype, supporting specificity | Posted 2024-01-11 | https://doi.org/10.1101/2024.01.09.574075 | (hassett2024characterizingcsnk2a1mutantinduced pages 7-9, hassett2024characterizingcsnk2a1mutantinduced pages 1-4, hassett2024characterizingcsnk2a1mutantinduced pages 4-7) |
| Zebrafish rescue experiments | Functional rescue assay | Co-injection of mutant and wild-type CSNK2A1 mRNA (e.g., R191X with WT at 1:2; equal WT with Y50C) | Wild-type co-expression significantly rescued or attenuated mutant-induced abnormalities, supporting direct causal effects of CSNK2A1 dysfunction and therapeutic relevance of restoring WT function | Posted 2024-01-11 | https://doi.org/10.1101/2024.01.09.574075 | (hassett2024characterizingcsnk2a1mutantinduced pages 7-9, hassett2024characterizingcsnk2a1mutantinduced pages 1-4, hassett2024characterizingcsnk2a1mutantinduced pages 4-7) |
| Zebrafish CK2 inhibitor phenocopy | Pharmacologic perturbation model | Embryos treated with CX-4945 (CK2 inhibitor) in dose-response experiments | CK2 inhibition caused dose-dependent mortality and abnormal morphology, phenocopying developmental disruption from CSNK2A1 mutant expression and implicating CK2 pathway dysfunction | Posted 2024-01-11 | https://doi.org/10.1101/2024.01.09.574075 | (hassett2024characterizingcsnk2a1mutantinduced pages 7-9, hassett2024characterizingcsnk2a1mutantinduced pages 4-7, hassett2024characterizingcsnk2a1mutantinduced pages 12-18) |
| CSNK2A1 cilia / centrosome cell biology model | Cell biology / mechanistic model | BioID, CRISPR screening, GFP pulldown, and superresolution microscopy used to study CSNK2A1 localization and function in cilia biology | CSNK2A1 identified as a centrosomal protein concentrated at the mother centriole/distal appendages; modulates TTBK2 function in ciliary trafficking; mutant cilia were longer and unstable at the tip | Published 2021-04 | https://doi.org/10.1073/pnas.2018740118 | (loukil2021acomplexof pages 1-2, loukil2021acomplexof pages 2-3) |
| OCNDS-associated variant cilia defect assay | Variant-expression cell assay | Overexpression of OCNDS-associated CSNK2A1 variants in wild-type cells | OCNDS-linked variants caused ciliary structural abnormalities, providing a mechanistic bridge from genotype to developmental cell-biology defects | Published 2021-04 | https://doi.org/10.1073/pnas.2018740118 | (loukil2021acomplexof pages 1-2) |
| CSNK2A1 Foundation registry / research infrastructure | Patient registry / natural history / advocacy infrastructure | Foundation-established OCNDS registry with patient enrollment, variant tracking, grant support, and research-roadmap development | Registry includes >200 registered patients with ~40 additional known globally; foundation reported 82 distinct variants and 22 distinct deletions; supports natural history, biomarker development, toolbox expansion, and therapeutic planning | Published 2024-01 | https://doi.org/10.1177/26330040241249763 | (rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2) |
| Simons Searchlight | Observational natural history study / research platform | International, prospective, family-based online observational study for rare neurodevelopmental genetic conditions, explicitly including CSNK2A1 | Collects medical, behavioral, learning, developmental, and biospecimen data longitudinally to improve clinical care and treatment research; useful real-world infrastructure for OCNDS natural history and outcome tracking | Study first posted 2010-11-10; recruiting; last update posted 2025-06-06 | https://clinicaltrials.gov/study/NCT01238250 | (NCT01238250 chunk 1) |
| Simons Searchlight OCNDS family survey | Patient-reported outcomes infrastructure | 2022 family survey within Simons Searchlight | Identified top family concerns in OCNDS as intellectual disability/developmental delay, language delay/inability to speak, and sleep issues; 77% of families reported sleep-related disruptions | Reported in 2024 perspective | https://doi.org/10.1177/26330040241249763 | (rushing2024patientorganizationperspective pages 2-4, rushing2024patientorganizationperspective pages 1-2) |
Table: This table summarizes the main experimental models and real-world research infrastructure currently supporting OCNDS/CSNK2A1 research. It highlights how zebrafish and cell-biology systems inform mechanism, while registries and observational studies enable natural-history and translational work.
Interpretation and expert analysis (authoritative synthesis): - 2024 patient-organization and research-roadmap work explicitly frames OCNDS mechanism as unresolved and likely heterogeneous across variants (“loss of function or altered substrate specificity”), and emphasizes the translational need for biomarkers and therapeutic testing pipelines, including drug repurposing and gene therapy. (rushing2024patientorganizationperspective pages 1-2, rushing2024patientorganizationperspective pages 2-4) - The combination of (i) substrate-specificity “rewiring” for K198R, (ii) NMD/haploinsufficiency for null variants, and (iii) cilia structural defects from OCNDS variant expression provides a coherent mechanistic landscape in which different CSNK2A1 variants may cause disease via distinct biochemical routes, converging on neurodevelopmental phenotypes. (caefer2022theokurchungneurodevelopmental pages 1-2, nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2, loukil2021acomplexof pages 1-2)
References
(chung2022okurchungneurodevelopmentalsyndrome pages 1-3): W Chung and V Okur. Okur-chung neurodevelopmental syndrome. Unknown journal, 2022.
(chung2022okurchungneurodevelopmentalsyndrome pages 3-6): W Chung and V Okur. Okur-chung neurodevelopmental syndrome. Unknown journal, 2022.
(rushing2024patientorganizationperspective pages 1-2): Gabrielle V. Rushing and Jennifer Sills. Patient organization perspective: a research roadmap for okur-chung neurodevelopmental syndrome. Therapeutic Advances in Rare Disease, Jan 2024. URL: https://doi.org/10.1177/26330040241249763, doi:10.1177/26330040241249763. This article has 2 citations.
(blanc2024patientwitha pages 1-2): Albin Blanc, Céline Bonnet, Marion Wandzel, Virginie Roth, Yannis Duffourd, Hanna Safraou, Bruno Leheup, Florence Muller, Julie D Colne, François Feillet, Emmanuelle Schmitt, Matheus Castro, Jullian Savatt, Adriano Burcheri, Christophe Nemos, Christophe Philippe, and Laëtitia Lambert. Patient with a heterozygous pathogenic variant in csnk2a1 gene: a new case to update the okur–chung neurodevelopmental syndrome. American Journal of Medical Genetics Part A, May 2024. URL: https://doi.org/10.1002/ajmg.a.63642, doi:10.1002/ajmg.a.63642. This article has 3 citations.
(OpenTargets Search: Okur-Chung neurodevelopmental syndrome-CSNK2A1): Open Targets Query (Okur-Chung neurodevelopmental syndrome-CSNK2A1, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(belnap2023inheritedcsnk2a1variants pages 1-2): Newell Belnap, Aiai Price‐Smith, Keri Ramsey, Kamawela Leka, Anna Abraham, Emma Lieberman, Katie Hassett, Sai Potu, Natasha Rudy, Kirstin Smith, Fady M. Mikhail, Kirstin G. Monaghan, Andrea Hendershot, Jeroen Mourmans, Maria Descartes, Matthew J. Huentelman, Jennifer Sills, Sampath Rangasamy, and Vinodh Narayanan. Inherited csnk2a1 variants in families with okur‐chung neurodevelopmental syndrome. Clinical Genetics, 104:607-609, Jul 2023. URL: https://doi.org/10.1111/cge.14408, doi:10.1111/cge.14408. This article has 8 citations and is from a peer-reviewed journal.
(rushing2024patientorganizationperspective pages 2-4): Gabrielle V. Rushing and Jennifer Sills. Patient organization perspective: a research roadmap for okur-chung neurodevelopmental syndrome. Therapeutic Advances in Rare Disease, Jan 2024. URL: https://doi.org/10.1177/26330040241249763, doi:10.1177/26330040241249763. This article has 2 citations.
(nan2024okur‐chungneurodevelopmentalsyndrome pages 1-2): Haitian Nan, Min-Liang Chu, Jing Zhang, Deming Jiang, Yihao Wang, and Liyong Wu. Okur‐chung neurodevelopmental syndrome: implications for phenotype and genotype expansion. Molecular Genetics & Genomic Medicine, Mar 2024. URL: https://doi.org/10.1002/mgg3.2398, doi:10.1002/mgg3.2398. This article has 9 citations and is from a peer-reviewed journal.
(blanc2024patientwitha pages 4-5): Albin Blanc, Céline Bonnet, Marion Wandzel, Virginie Roth, Yannis Duffourd, Hanna Safraou, Bruno Leheup, Florence Muller, Julie D Colne, François Feillet, Emmanuelle Schmitt, Matheus Castro, Jullian Savatt, Adriano Burcheri, Christophe Nemos, Christophe Philippe, and Laëtitia Lambert. Patient with a heterozygous pathogenic variant in csnk2a1 gene: a new case to update the okur–chung neurodevelopmental syndrome. American Journal of Medical Genetics Part A, May 2024. URL: https://doi.org/10.1002/ajmg.a.63642, doi:10.1002/ajmg.a.63642. This article has 3 citations.
(belnap2023inheritedcsnk2a1variants pages 2-2): Newell Belnap, Aiai Price‐Smith, Keri Ramsey, Kamawela Leka, Anna Abraham, Emma Lieberman, Katie Hassett, Sai Potu, Natasha Rudy, Kirstin Smith, Fady M. Mikhail, Kirstin G. Monaghan, Andrea Hendershot, Jeroen Mourmans, Maria Descartes, Matthew J. Huentelman, Jennifer Sills, Sampath Rangasamy, and Vinodh Narayanan. Inherited csnk2a1 variants in families with okur‐chung neurodevelopmental syndrome. Clinical Genetics, 104:607-609, Jul 2023. URL: https://doi.org/10.1111/cge.14408, doi:10.1111/cge.14408. This article has 8 citations and is from a peer-reviewed journal.
(caefer2022theokurchungneurodevelopmental pages 1-2): Danielle M. Caefer, Nhat Q. Phan, Jennifer C. Liddle, Jeremy L. Balsbaugh, Joseph P. O’Shea, Anastasios V. Tzingounis, and Daniel Schwartz. The okur-chung neurodevelopmental syndrome mutation ck2k198r leads to a rewiring of kinase specificity. Frontiers in Molecular Biosciences, Apr 2022. URL: https://doi.org/10.3389/fmolb.2022.850661, doi:10.3389/fmolb.2022.850661. This article has 14 citations.
(blanc2024patientwitha pages 4-4): Albin Blanc, Céline Bonnet, Marion Wandzel, Virginie Roth, Yannis Duffourd, Hanna Safraou, Bruno Leheup, Florence Muller, Julie D Colne, François Feillet, Emmanuelle Schmitt, Matheus Castro, Jullian Savatt, Adriano Burcheri, Christophe Nemos, Christophe Philippe, and Laëtitia Lambert. Patient with a heterozygous pathogenic variant in csnk2a1 gene: a new case to update the okur–chung neurodevelopmental syndrome. American Journal of Medical Genetics Part A, May 2024. URL: https://doi.org/10.1002/ajmg.a.63642, doi:10.1002/ajmg.a.63642. This article has 3 citations.
(zhuri2024acaseof pages 3-6): Drenushe Zhuri, Fulya Dusenkalkan, Guzin Tunca Alparslan, and Hakan Gurkan. A case of okur-chung neurodevelopmental syndrome with a novel, de novo variant on the csnk2a1 gene in a turkish patient. Molecular Syndromology, 15:43-50, May 2024. URL: https://doi.org/10.1159/000530585, doi:10.1159/000530585. This article has 5 citations and is from a peer-reviewed journal.
(zhuri2024acaseof pages 1-3): Drenushe Zhuri, Fulya Dusenkalkan, Guzin Tunca Alparslan, and Hakan Gurkan. A case of okur-chung neurodevelopmental syndrome with a novel, de novo variant on the csnk2a1 gene in a turkish patient. Molecular Syndromology, 15:43-50, May 2024. URL: https://doi.org/10.1159/000530585, doi:10.1159/000530585. This article has 5 citations and is from a peer-reviewed journal.
(zhuri2024acaseof pages 6-7): Drenushe Zhuri, Fulya Dusenkalkan, Guzin Tunca Alparslan, and Hakan Gurkan. A case of okur-chung neurodevelopmental syndrome with a novel, de novo variant on the csnk2a1 gene in a turkish patient. Molecular Syndromology, 15:43-50, May 2024. URL: https://doi.org/10.1159/000530585, doi:10.1159/000530585. This article has 5 citations and is from a peer-reviewed journal.
(nan2024okur‐chungneurodevelopmentalsyndrome pages 2-5): Haitian Nan, Min-Liang Chu, Jing Zhang, Deming Jiang, Yihao Wang, and Liyong Wu. Okur‐chung neurodevelopmental syndrome: implications for phenotype and genotype expansion. Molecular Genetics & Genomic Medicine, Mar 2024. URL: https://doi.org/10.1002/mgg3.2398, doi:10.1002/mgg3.2398. This article has 9 citations and is from a peer-reviewed journal.
(hassett2024characterizingcsnk2a1mutantinduced pages 7-9): Katie Hassett, Sai Srihaas Potu, Aravind Sankaramoorthy, Sukanniya Kaneshamoorthy, Kamawela Leka, Matthew J. Huentelman, Vinodh Narayanan, and Sampath Rangasamy. Characterizing csnk2a1 mutant-induced morphological phenotypes in zebrafish (danio rerio): insights into okur-chung neurodevelopmental syndrome (ocnds). bioRxiv, Jan 2024. URL: https://doi.org/10.1101/2024.01.09.574075, doi:10.1101/2024.01.09.574075. This article has 0 citations.
(hassett2024characterizingcsnk2a1mutantinduced pages 1-4): Katie Hassett, Sai Srihaas Potu, Aravind Sankaramoorthy, Sukanniya Kaneshamoorthy, Kamawela Leka, Matthew J. Huentelman, Vinodh Narayanan, and Sampath Rangasamy. Characterizing csnk2a1 mutant-induced morphological phenotypes in zebrafish (danio rerio): insights into okur-chung neurodevelopmental syndrome (ocnds). bioRxiv, Jan 2024. URL: https://doi.org/10.1101/2024.01.09.574075, doi:10.1101/2024.01.09.574075. This article has 0 citations.
(hassett2024characterizingcsnk2a1mutantinduced pages 4-7): Katie Hassett, Sai Srihaas Potu, Aravind Sankaramoorthy, Sukanniya Kaneshamoorthy, Kamawela Leka, Matthew J. Huentelman, Vinodh Narayanan, and Sampath Rangasamy. Characterizing csnk2a1 mutant-induced morphological phenotypes in zebrafish (danio rerio): insights into okur-chung neurodevelopmental syndrome (ocnds). bioRxiv, Jan 2024. URL: https://doi.org/10.1101/2024.01.09.574075, doi:10.1101/2024.01.09.574075. This article has 0 citations.
(li2025acaseof pages 1-2): Xin Li, Shuping Wang, Xin Liu, Zhenjing Wang, Na Lv, Shaoting Wang, and Wentao Yang. A case of
(li2025acaseof pages 3-4): Xin Li, Shuping Wang, Xin Liu, Zhenjing Wang, Na Lv, Shaoting Wang, and Wentao Yang. A case of
(loukil2021acomplexof pages 1-2): Abdelhalim Loukil, Chloe Barrington, and Sarah C. Goetz. A complex of distal appendage–associated kinases linked to human disease regulates ciliary trafficking and stability. Proceedings of the National Academy of Sciences, Apr 2021. URL: https://doi.org/10.1073/pnas.2018740118, doi:10.1073/pnas.2018740118. This article has 33 citations and is from a highest quality peer-reviewed journal.
(khamirani2022clinicalfeaturesof pages 5-6): Hossein Jafari Khamirani, Sina Zoghi, Ali Motealleh, Mehdi Dianatpour, Seyed Mohammad Bagher Tabei, Sanaz Mohammadi, and Seyed Alireza Dastgheib. Clinical features of okur-chung neurodevelopmental syndrome: case report and literature review. Molecular Syndromology, 13:381-388, Mar 2022. URL: https://doi.org/10.1159/000522353, doi:10.1159/000522353. This article has 18 citations and is from a peer-reviewed journal.
(NCT01238250 chunk 1): Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight. Simons Searchlight. 2010. ClinicalTrials.gov Identifier: NCT01238250
(hassett2024characterizingcsnk2a1mutantinduced pages 12-18): Katie Hassett, Sai Srihaas Potu, Aravind Sankaramoorthy, Sukanniya Kaneshamoorthy, Kamawela Leka, Matthew J. Huentelman, Vinodh Narayanan, and Sampath Rangasamy. Characterizing csnk2a1 mutant-induced morphological phenotypes in zebrafish (danio rerio): insights into okur-chung neurodevelopmental syndrome (ocnds). bioRxiv, Jan 2024. URL: https://doi.org/10.1101/2024.01.09.574075, doi:10.1101/2024.01.09.574075. This article has 0 citations.
(loukil2021acomplexof pages 2-3): Abdelhalim Loukil, Chloe Barrington, and Sarah C. Goetz. A complex of distal appendage–associated kinases linked to human disease regulates ciliary trafficking and stability. Proceedings of the National Academy of Sciences, Apr 2021. URL: https://doi.org/10.1073/pnas.2018740118, doi:10.1073/pnas.2018740118. This article has 33 citations and is from a highest quality peer-reviewed journal.